{
  "eval_id": "S01",
  "eval_file": "evals/single/S01.json",
  "timestamp": "2025-09-18T16:44:09.732765Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is EMA-approved for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer who have received endocrine therapy and at least two prior systemic therapiesâ€”including a CDK4/6 inhibitor. Please review the SmPC for full details on efficacy, safety, and patient selection, and if you can, email me the latest EMA label for reference."
}